γ-linolenic acid (Borage Oil) / Trx Cancer Research Results

GLA, γ-linolenic acid (Borage Oil): Click to Expand ⟱
Features:

γ-Linolenic acid (GLA) — an omega-6 polyunsaturated fatty acid (18:3 n-6) found in high concentration in borage oil, evening primrose oil, and blackcurrant seed oil. Metabolized to dihomo-γ-linolenic acid (DGLA) → precursor of anti-inflammatory eicosanoids (e.g., PGE1).

Primary mechanisms (conceptual rank):
1) Membrane lipid remodeling → altered eicosanoid balance (↑ PGE1; DGLA-derived metabolites)
2) Modulation of inflammatory signaling (↓ NF-κB tone; context-dependent)
3) Lipid peroxidation susceptibility (PUFA-driven ROS shifts)
4) Potential anti-proliferative effects (high concentration only; tumor models)
5) Metabolic signaling interaction (PPAR activation context-dependent)

Bioavailability / PK relevance: Orally absorbed and incorporated into membrane phospholipids; rapidly elongated to DGLA. Plasma levels achievable with supplementation; cellular effects reflect incorporation over days–weeks (remodeling).

In-vitro vs oral exposure: Direct tumor cytotoxicity generally observed at supra-physiologic concentrations; physiologic doses mainly alter lipid signaling rather than induce apoptosis.

Clinical evidence status: Used for inflammatory conditions (e.g., dermatitis, RA); oncology data limited and inconsistent; no cancer approval.

GLA (abundant in borage oil) has shown anti-proliferative and pro-apoptotic effects on multiple cancer cell lines and in animal models (mechanisms include ER stress, mitochondrial dysfunction, altered eicosanoid signaling).
-Borage plants can contain unsaturated PAs(Pyrrolizidine alkaloids) which are hepatotoxic and genotoxic/carcinogenic. Many authorities advise only using borage oil products certified PA-free, and caution against long-term or high-dose use.
-γ-gamma linolenic acid (GLA, 18:3n-6) are polyunsaturated fatty acids (PUFA) that improve the human health

γ-Linolenic Acid (Borage Oil) — Cancer vs Normal Cell Pathway Map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Membrane lipid remodeling (DGLA incorporation) ↑ substrate (context-dependent) ↑ membrane incorporation G Phospholipid composition shift Changes membrane fluidity and eicosanoid substrate pool; time-dependent remodeling.
2 Eicosanoid balance (PGE1 vs AA-derived eicosanoids) ↔ / ↓ pro-inflammatory tone ↓ inflammation G Anti-inflammatory modulation DGLA-derived PGE1 often anti-inflammatory; may counterbalance arachidonic acid metabolites.
3 ROS / Lipid peroxidation ↑ (PUFA-dependent; dose-dependent) ↔ / ↑ (high dose) P/R Lipid oxidative susceptibility Highly unsaturated structure increases peroxidation potential; may sensitize tumors to oxidative stress.
4 NF-κB ↓ (context-dependent) ↓ R/G Reduced inflammatory transcription Often secondary to altered eicosanoid signaling.
5 PPAR (α/γ) ↑ (model-dependent) ↑ R/G Lipid metabolic regulation GLA and derivatives may activate PPAR pathways influencing lipid and glucose metabolism.
6 Apoptosis ↑ (high concentration only) ↔ R/G Mitochondrial apoptosis (experimental) Reported in certain tumor lines at supra-physiologic levels.
7 Ferroptosis ↑ (theoretical; PUFA-linked) ↔ R/G Lipid peroxidation vulnerability PUFA enrichment can enhance ferroptotic susceptibility depending on antioxidant context.
8 HIF-1α ↔ (limited evidence) ↔ G Not primary axis No consistent direct modulation reported.
9 NRF2 ↔ / ↑ (adaptive; context-dependent) ↔ R/G Redox-response adjustment May activate antioxidant response secondary to lipid peroxidation stress.
10 Ca²⁺ signaling ↔ (membrane-dependent) ↔ P/R Membrane microdomain modulation Changes in lipid composition can subtly influence ion channel behavior.
11 Clinical Translation Constraint ↓ (constraint) ↓ (constraint) — Context-dependent effects Physiologic doses primarily anti-inflammatory; anti-cancer cytotoxicity not clinically established.

TSF legend:
P: 0–30 min (lipid oxidation events)
R: 30 min–3 hr (acute signaling shifts)
G: >3 hr (membrane remodeling and phenotype changes)
Trx, Thioredoxin: Click to Expand ⟱
Source:
Type: protein
Trx is a small protein that acts as a reducing agent, donating electrons to reduce oxidized proteins and other molecules.
Trx is overexpressed in various types of cancer, including breast, lung, colon, and prostate cancer.

- Cytosolic thioredoxin (TRX-1) and mitochondrial thioredoxin (TRX-2).

- Thioredoxin is a pivotal redox regulator that protects cells from oxidative stress and supports survival and proliferation.

- There is interest in combining thioredoxin inhibitors with conventional chemotherapy or radiotherapy to sensitize tumors to oxidative stress and improve treatment efficacy.
Scientific Papers found: Click to Expand⟱
4513- GLA,    Antineoplastic Effects of Gamma Linolenic Acid on Hepatocellular Carcinoma Cell Lines
- in-vitro, Liver, HUH7
TumCP↓, ROS↑, Apoptosis↑, HO-1↑, Trx↑, lipid-P↑, eff↓, MMP↓, DNAdam↑, selectivity↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

HO-1↑, 1,   lipid-P↑, 1,   ROS↑, 1,   Trx↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,  

Migration ⓘ

TumCP↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↓, 1,   selectivity↑, 1,  
Total Targets: 10

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Trx, Thioredoxin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:374  Target#:824  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page